Lisanti Capital Growth LLC Invests $1.31 Million in Beta Bionics, Inc. $BBNX

Posted by on May 24th, 2026

Lisanti Capital Growth LLC bought a new position in Beta Bionics, Inc. (NASDAQ:BBNX – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 42,985 shares of the company’s stock, valued at approximately $1,310,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in BBNX. GPS Wealth Strategies Group LLC boosted its holdings in Beta Bionics by 45.0% in the third quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock valued at $29,000 after acquiring an additional 450 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in Beta Bionics by 203.6% during the third quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock valued at $47,000 after buying an additional 1,594 shares during the period. Strs Ohio purchased a new position in Beta Bionics during the first quarter valued at $29,000. Ameritas Investment Partners Inc. lifted its position in Beta Bionics by 139.1% during the third quarter. Ameritas Investment Partners Inc. now owns 3,202 shares of the company’s stock valued at $64,000 after buying an additional 1,863 shares during the period. Finally, Legal & General Group Plc lifted its position in Beta Bionics by 197.4% during the second quarter. Legal & General Group Plc now owns 3,976 shares of the company’s stock valued at $58,000 after buying an additional 2,639 shares during the period.

Beta Bionics Price Performance

Beta Bionics stock opened at $11.82 on Friday. Beta Bionics, Inc. has a one year low of $8.80 and a one year high of $32.71. The business’s fifty day moving average is $10.58 and its 200 day moving average is $18.21. The stock has a market capitalization of $526.72 million, a PE ratio of -7.83 and a beta of 3.29.

Beta Bionics (NASDAQ:BBNX – Get Free Report) last issued its earnings results on Tuesday, April 21st. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.04. The business had revenue of $27.63 million during the quarter. Beta Bionics had a negative return on equity of 23.00% and a negative net margin of 60.27%. As a group, sell-side analysts expect that Beta Bionics, Inc. will post -2.19 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on BBNX shares. Truist Financial lowered their price objective on Beta Bionics from $25.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, April 15th. Robert W. Baird lowered their price objective on Beta Bionics from $28.00 to $14.00 and set a “neutral” rating for the company in a research report on Wednesday, February 18th. TD Cowen initiated coverage on Beta Bionics in a research report on Monday, January 26th. They issued a “hold” rating and a $17.00 price target for the company. Weiss Ratings lowered shares of Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, April 21st. Finally, The Goldman Sachs Group cut their price target on shares of Beta Bionics from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, April 9th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $20.00.

View Our Latest Stock Report on BBNX

About Beta Bionics

(Free Report)

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.

Read More

Want to see what other hedge funds are holding BBNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Beta Bionics, Inc. (NASDAQ:BBNX – Free Report).

Institutional Ownership by Quarter for Beta Bionics (NASDAQ:BBNX)

Receive News & Ratings for Beta Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beta Bionics and related companies with MarketBeat.com's FREE daily email newsletter.